Checkpoint Inhibitor–Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes
Article 2019 en
Authors
VT
Venessa Tsang
RM
Rachel T. McGrath
RC
Roderick Clifton‐Bligh
Abstract
1 min read
CIADM is characterized by sudden permanent β-cell failure occurring after immunotherapy. It is distinct from T1D, usually lacks DAA or T1D-associated HLA-risk haplotypes, and is associated with difficult glycemic control from the onset. As such, CIADM represents a new model of auto-inflammatory β-cell failure.
Linda Wu, John M. Wentworth, Christopher Liddle, Nicole Fewings, Matteo S. Carlino, David A. Brown, Roderick Clifton‐Bligh, Georgina V. Long, Richard A Scolyer, Nicholas Norris, Sarah C. Sasson, Venessa Tsang, Alexander M. Menzies, Jenny E. Gunton
Venessa Tsang, Rachel T. McGrath, Roderick Clifton‐Bligh, Richard A Scolyer, Valerie Jakrot, Alexander Guminski, Georgina V. Long, Alexander M. Menzies
Discussion(0)
No comments yet. Be the first to comment.